Hirokazu Nagai

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma

Atsushi Ichikawa, Tomohiro Kinoshita, Takashi Watanabe et al. · New England Journal of Medicine · 1997 · 278 citations

Medicine, Molecular Genetics, Oncology +9

Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes

Toshiki Uchida, Tomohiro Kinoshita, Hirokazu Nagai et al. · Blood · 1997 · 261 citations · Full text

Medicine, Genetics, Molecular Genetics +13

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.

Masataka Ohta, Hirokazu Nagai, Makiko Shimizu et al. · PubMed · 1994 · 169 citations

Life Sciences, Genetics, Molecular Genetics +17